List of Chapters/Sections(Table Of Content)
1 Study Coverage
1.1 Alpha- Antitrypsin Deficiency Treatment Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Introduction
1.2 Global Alpha- Antitrypsin Deficiency Treatment Outlook 2017 VS 2022 VS 2028
1.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028
1.2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028
1.3 Alpha- Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Alpha- Antitrypsin Deficiency Treatment in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Alpha- Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Alpha- Antitrypsin Deficiency Treatment Market Dynamics
1.4.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
1.4.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers
1.4.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
1.4.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Alpha- Antitrypsin Deficiency Treatment by Type
2.1 Alpha- Antitrypsin Deficiency Treatment Market Segment by Type
2.1.1 CT-2009
2.1.2 POL-6014
2.1.3 ARO-AAT
2.1.4 ALNAAT-02
2.1.5 Others
2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017, 2022 & 2028)
2.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2028)
2.4 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017, 2022 & 2028)
2.5 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2028)
3 Alpha- Antitrypsin Deficiency Treatment by Application
3.1 Alpha- Antitrypsin Deficiency Treatment Market Segment by Application
3.1.1 Clinic
3.1.2 Hospital
3.1.3 Others
3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017, 2022 & 2028)
3.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2028)
3.4 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017, 2022 & 2028)
3.5 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2028)
4 Global Alpha- Antitrypsin Deficiency Treatment Competitor Landscape by Company
4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Company
4.1.1 Top Global Alpha- Antitrypsin Deficiency Treatment Companies Ranked by Revenue (2021)
4.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue by Player (2017-2022)
4.2 Global Alpha- Antitrypsin Deficiency Treatment Concentration Ratio (CR)
4.2.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Alpha- Antitrypsin Deficiency Treatment in 2021
4.2.3 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Alpha- Antitrypsin Deficiency Treatment Headquarters, Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
4.3.1 Global Alpha- Antitrypsin Deficiency Treatment Headquarters and Area Served
4.3.2 Global Alpha- Antitrypsin Deficiency Treatment Companies Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Alpha- Antitrypsin Deficiency Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Company
4.5.1 Top Alpha- Antitrypsin Deficiency Treatment Players in United States, Ranked by Revenue (2021)
4.5.2 United States Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region
5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2017-2028)
5.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region: 2017-2022
5.2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.1.2 North America Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.3.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.4.2 Latin America Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Adverum Biotechnologies, Inc.
7.1.1 Adverum Biotechnologies, Inc. Company Details
7.1.2 Adverum Biotechnologies, Inc. Business Overview
7.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.1.5 Adverum Biotechnologies, Inc. Recent Development
7.2 Alnylam Pharmaceuticals, Inc.
7.2.1 Alnylam Pharmaceuticals, Inc. Company Details
7.2.2 Alnylam Pharmaceuticals, Inc. Business Overview
7.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
7.3 Applied Genetic Technologies Corporation
7.3.1 Applied Genetic Technologies Corporation Company Details
7.3.2 Applied Genetic Technologies Corporation Business Overview
7.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
7.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.3.5 Applied Genetic Technologies Corporation Recent Development
7.4 Arrowhead Pharmaceuticals, Inc.
7.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
7.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview
7.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
7.5 Carolus Therapeutics, Inc.
7.5.1 Carolus Therapeutics, Inc. Company Details
7.5.2 Carolus Therapeutics, Inc. Business Overview
7.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.5.5 Carolus Therapeutics, Inc. Recent Development
7.6 Cevec Pharmaceuticals GmbH
7.6.1 Cevec Pharmaceuticals GmbH Company Details
7.6.2 Cevec Pharmaceuticals GmbH Business Overview
7.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
7.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.6.5 Cevec Pharmaceuticals GmbH Recent Development
7.7 Dicerna Pharmaceuticals, Inc.
7.7.1 Dicerna Pharmaceuticals, Inc. Company Details
7.7.2 Dicerna Pharmaceuticals, Inc. Business Overview
7.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
7.8 Digna Biotech, S.L.
7.8.1 Digna Biotech, S.L. Company Details
7.8.2 Digna Biotech, S.L. Business Overview
7.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
7.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.8.5 Digna Biotech, S.L. Recent Development
7.9 Editas Medicine, Inc.
7.9.1 Editas Medicine, Inc. Company Details
7.9.2 Editas Medicine, Inc. Business Overview
7.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.9.5 Editas Medicine, Inc. Recent Development
7.10 Grifols, S.A.
7.10.1 Grifols, S.A. Company Details
7.10.2 Grifols, S.A. Business Overview
7.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
7.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.10.5 Grifols, S.A. Recent Development
7.11 Inhibrx
7.11.1 Inhibrx Company Details
7.11.2 Inhibrx Business Overview
7.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
7.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.11.5 Inhibrx Recent Development
7.12 Intellia Therapeutics, Inc.
7.12.1 Intellia Therapeutics, Inc. Company Details
7.12.2 Intellia Therapeutics, Inc. Business Overview
7.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.12.5 Intellia Therapeutics, Inc. Recent Development
7.13 International Stem Cell Corporation
7.13.1 International Stem Cell Corporation Company Details
7.13.2 International Stem Cell Corporation Business Overview
7.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
7.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.13.5 International Stem Cell Corporation Recent Development
7.14 Ionis Pharmaceuticals, Inc.
7.14.1 Ionis Pharmaceuticals, Inc. Company Details
7.14.2 Ionis Pharmaceuticals, Inc. Business Overview
7.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.14.5 Ionis Pharmaceuticals, Inc. Recent Development
7.15 Kamada Ltd.
7.15.1 Kamada Ltd. Company Details
7.15.2 Kamada Ltd. Business Overview
7.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
7.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.15.5 Kamada Ltd. Recent Development
7.16 Polyphor Ltd.
7.16.1 Polyphor Ltd. Company Details
7.16.2 Polyphor Ltd. Business Overview
7.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
7.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.16.5 Polyphor Ltd. Recent Development
7.17 ProMetic Life Sciences Inc.
7.17.1 ProMetic Life Sciences Inc. Company Details
7.17.2 ProMetic Life Sciences Inc. Business Overview
7.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.17.5 ProMetic Life Sciences Inc. Recent Development
7.18 rEVO Biologics, Inc.
7.18.1 rEVO Biologics, Inc. Company Details
7.18.2 rEVO Biologics, Inc. Business Overview
7.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.18.5 rEVO Biologics, Inc. Recent Development
7.19 Sangamo BioSciences, Inc.
7.19.1 Sangamo BioSciences, Inc. Company Details
7.19.2 Sangamo BioSciences, Inc. Business Overview
7.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
7.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
7.19.5 Sangamo BioSciences, Inc. Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
